Harshil Shah
Icahn School of Medicine at Mount Sinai
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Harshil Shah.
American Journal of Cardiology | 2016
Sidakpal S. Panaich; Shilpkumar Arora; Nilay Patel; Nileshkumar J. Patel; Samir V. Patel; Chirag Savani; Vikas Singh; Sunny Jhamnani; Rajesh Sonani; Sopan Lahewala; Badal Thakkar; Achint Patel; Abhishek Dave; Harshil Shah; Parth Bhatt; Radhika Jaiswal; Abhijit Ghatak; Vishal Gupta; Abhishek Deshmukh; Ashok Kondur; Theodore Schreiber; Cindy L. Grines; Apurva Badheka
Contemporary data on clinical outcomes after utilization of atherectomy in lower extremity endovascular revascularization are sparse. The study cohort was derived from Healthcare Cost and Utilization Project nationwide inpatient sample database from the year 2012. Peripheral endovascular interventions including atherectomy were identified using appropriate International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic and procedural codes. The subjects were divided and compared in 2 groups: atherectomy versus no atherectomy. Two-level hierarchical multivariate mixed models were created. The coprimary outcomes were in-hospital mortality and amputation; secondary outcome was a composite of in-hospital mortality and periprocedural complications. Hospitalization costs were also assessed. Atherectomy utilization (odds ratio, 95% CI, p value) was independently predictive of lower in-hospital mortality (0.46, 0.28 to 0.75, 0.002) and lower amputation rates (0.83, 0.71 to 0.97, 0.020). Atherectomy use was also predictive of significantly lower secondary composite outcome of in-hospital mortality and complications (0.79, 0.69 to 0.90, 0.001). In the propensity-matched cohort, atherectomy utilization was again associated with a lower rate of amputation (11.18% vs 12.92%, p = 0.029), in-hospital mortality (0.71% vs 1.53%, p 0.001), and any complication (13.24% vs 16.09%, p 0.001). However, atherectomy use was also associated with higher costs (
American Journal of Cardiology | 2016
Shilpkumar Arora; Sidakpal S. Panaich; Nilay Patel; Nileshkumar J. Patel; Chirag Savani; Samir V. Patel; Badal Thakkar; Rajesh Sonani; Sunny Jhamnani; Vikas Singh; Sopan Lahewala; Achint Patel; Parth Bhatt; Harshil Shah; Radhika Jaiswal; Vishal Gupta; Abhishek Deshmukh; Ashok Kondur; Theodore Schreiber; Apurva Badheka; Cindy L. Grines
24,790 ± 397 vs
International Journal of Cardiology | 2017
Sopan Lahewala; Shilpkumar Arora; Prashant Patel; Varun Kumar; Nirali Patel; Byomesh Tripathi; Nilay Patel; Kamala Ramya Kallur; Harshil Shah; Amer K. Syed; Umesh Gidwani; Juan F. Viles-Gonzalez; Abhishek Deshmukh
22635 ± 251, p <0.001). Atherectomy use in conjunction with angioplasty (with or without stenting) was associated with improved in-hospital outcomes in terms of lower amputation rates, mortality, and postprocedural complications.
Journal of Cardiac Failure | 2018
Ashish Correa; Achint Patel; Kinsuk Chauhan; Harshil Shah; Aparna Saha; Mihir Dave; Priti Poojary; Abhishek Mishra; Narender Annapureddy; Shaman Dalal; Ioannis Konstantinidis; Renu Nimma; Shiv Kumar Agarwal; Lili Chan; Girish N. Nadkarni; Sean Pinney
Contemporary real-world data on clinical outcomes after utilization of coronary atherectomy are sparse. The study cohort was derived from Healthcare Cost and Utilization Project Nationwide Inpatient Sample database from year 2012. Percutaneous coronary interventions including atherectomy were identified using appropriate International Classification of Diseases, 9th Revision diagnostic and procedural codes. Two-level hierarchical multivariate mixed models were created. The primary outcome was a composite of in-hospital mortality and periprocedural complications; the secondary outcome was in-hospital mortality. Hospitalization costs were also assessed. A total of 107,131 procedures were identified in 2012. Multivariate analysis revealed that atherectomy utilization was independently predictive of greater primary composite outcome of in-hospital mortality and complications (odds ratio 1.34, 95% confidence interval 1.22 to 1.47, p <0.001) but was not associated with any significant difference in terms of in-hospital mortality alone (odds ratio 1.22, 95% confidence interval 0.99 to 1.52, p 0.063). In the propensity-matched cohort, atherectomy utilization was again associated with a higher rate of complications (12.88% vs 10.99%, p = 0.001), in-hospital mortality +a ny complication (13.69% vs 11.91%, p = 0.003) with a nonsignificant difference in terms of in-hospital mortality alone (3.45% vs 2.88%, p = 0.063) and higher hospitalization costs (
European Journal of Preventive Cardiology | 2018
Safi U. Khan; Swapna Talluri; Hammad Rahman; Manidhar Lekkala; Muhammad Shahzeb Khan; Haris Riaz; Harshil Shah; Edo Kaluski; Sudhakar Sattur
25,341 ± 353 vs
Clinical Cardiology | 2018
Purav Shah; Shilpkumar Arora; Varun Kumar; Surina Sharma; Harshil Shah; Byomesh Tripathi; Purnima Sharma; Ravina Sharma; Sejal Savani; Muhammad Raheel Qureshi; Ibrahim Faruqi
21,984 ± 87, p <0.001). Atherectomy utilization during percutaneous coronary intervention is associated with a higher rate of postprocedural complications without any significant impact on in-hospital mortality.
Journal of Critical Care | 2017
Uvesh Mansuri; Achint Patel; Harshil Shah; Kinsuk Chauhan; Priti Poojary; Aparna Saha; Mihir Dave; Arpita Hazra; Tushar Mishra; Narender Annapureddy; Girish N. Nadkarni; Lili Chan
BACKGROUND CHADS2 and CHA2DS2-VASc scores are widely used for thromboembolic risk assessment in Atrial Fibrillation(AF) cohort, however further utilization to predict outcomes is understudied. METHOD HCUPs National Readmission Data(NRD) 2013 was queried for AF admissions using ICD-9-CM code 427.31 in principal diagnosis field. Patients with mitral valve disease or repair/or replacement were excluded to estimate population with non-valvular AF only. CHADS2 and CHA2DS2-VASc were calculated for each patient. Hierarchical two-level logistic and linear models were used to evaluate study outcomes in terms of mortality, 30 or 90-day readmissions, length of stay(LOS) and cost. RESULT Of 116,450 principal non-valvular AF admissions(50.2% female and 43.1% age≥75years) 29,179 patients were readmitted, with total 40,959 readmissions. Higher CHADS2 and CHA2DS2-VASc score were associated with increased mortality from 0.4% for CHADS2 of 0 to 3.2% for score of 6 and from 0.2% for CHA2DS2-VASc of 0 to 3.2% for score≥8. LOS increased from 2.20days for CHADS2 of 0 to 5.08days for score of 6, while cost increased from
Journal of Cardiovascular Electrophysiology | 2017
Byomesh Tripathi; Shilpkumar Arora; Abhishek Mishra; Vishwa Reddy Kundoor; Sopan Lahewala; Varun Kumar; Mahek Shah; Dhairya Lakhani; Harshil Shah; Nilay Patel; Nileshkumar J. Patel; Mihir Dave; Abhishek Deshmukh; Sattur Sudhakar; Radha Gopalan
7888 to
Journal of the American College of Cardiology | 2016
Sidakpal S. Panaich; Shilpkumar Arora; Nilay Patel; Smit Patel; Harshil Shah; Chirag Savani; Kriti Narwal; Kosha Thakore; Aditi Amin; Sopan Lahewala; Nileshkumar J. Patel; Ekta Aneja; Abhishek Deshmukh; Apurva Badheka
11,151. 30-day readmission rate increased from 8.9% for CHADS2 of 0 to 26.0% for score of 6, and 90-day readmission rate increased from 15.2% to 39%. CHA2DS2-VASc scoring similarly demonstrated a trend towards increasing readmission rate, LOS and cost for higher scores. Also, similar results were seen in hierarchical modeling with increment of CHADS2 and CHA2DS2-VASc scores. CONCLUSION CHADS2 and CHA2DS2-VASc scores can be used as quick surrogate markers for predicting outcomes beyond thromboembolic risk. Physician familiarity with these systems makes them easy to use bedside clinical tools to improve outcomes and resource allocation.
Journal of the American College of Cardiology | 2016
Prashant Patel; Shilpkumar Arora; Sopan Lahewala; Nilay Patel; Byomesh Tripathi; Purav Shah; Jaimin Trivedi; Harshil Shah; Chirag Bambhroliya; Smit Patel; Sidakpal S. Panaich; Abhishek Deshmukh; Apurva Badheka
BACKGROUND Dialysis-requiring acute kidney injury (D-AKI) is a serious complication in hospitalized heart failure (HF) patients. However, data on national trends are lacking after 2002. METHODS We used the Nationwide Inpatient Sample (2002-2013) to identify HF hospitalizations with and without D-AKI. We analyzed trends in incidence, in-hospital mortality, length of stay (LoS), and cost. We calculated adjusted odds ratios (aORs) for predictors of D-AKI and for outcomes including in-hospital mortality and adverse discharge (discharge to skilled nursing facilities, nursing homes, etc). RESULTS We identified 11,205,743 HF hospitalizations. Across 2002-2013, the incidence of D-AKI doubled from 0.51% to 1.09%. We found male sex, younger age, African-American and Hispanic race, and various comorbidities and procedures, such as sepsis and mechanical ventilation, to be independent predictors of D-AKI in HF hospitalizations. D-AKI was associated with higher odds of in-hospital mortality (aOR 2.49, 95% confidence interval [CI] 2.36-2.63; P < .01) and adverse discharge (aOR 2.04, 95% CI 1.95-2.13; P < .01). In-hospital mortality and attributable risk of mortality due to D-AKI decreased across 2002-2013. LoS and cost also decreased across this period. CONCLUSIONS The incidence of D-AKI in HF hospitalizations doubled across 2002-2013. Despite declining in-hospital mortality, LoS, and cost, D-AKI was associated with worse outcomes.